4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Conditions

• Hepatitis C, Chronic

Interventions

• DRUG: BI 207127 middle dose +SOC
• DRUG: BI 207127 high dose+SOC
• DRUG: Placebo + SOC
• DRUG: BI 207127 low dose + SOC

Sponsor

Boehringer Ingelheim